
FDA Grants Priority Review to Daiichi Sankyo–Merck’s First-in-Class Lung Cancer ADC
Previous articleIndia Moves Toward Affordable Semaglutide with Dr. Reddy’s Laboratories Approval
Next article PCI Unveils NEP-Aligned B.Pharm Curriculum for 2026–27 with Focus on AI and Industry Readiness
